• PRESAGE BIOSCIENCES

    A Pioneer In Translational Oncology

    We bring innovation to cancer drug development. Our platform is uniquely capable of unraveling complexities of how patient tumors respond to drug exposure.
  • A bridge between preclinical insights and patient care

    The Forefront of Translational Medicine

    Using Presage's patented CIVO (Comparative In Vivo Oncology) platform, tumor microenvironment response to multiple investigational treatments, alone or in combination, can be observed where it matters most—in a patient's tumor.

  • Presage’s proprietary drug development platform

    Uniquely Powerful Capabilities: The CIVO® Platform

    The CIVO (Comparative In Vivo Oncology) platform is an innovative translational oncology offering that encompasses a novel intratumoral delivery technology, a sophisticated operation, and highly detailed analysis. The platform is uniquely capable of providing comprehensive insights into the tumor microenvironment.
    PRESAGE BIOSCIENCES IS DRIVING THE FUTURE OF TRANSLATIONAL ONCOLOGY RESEARCH. WE ARE UNIQUELY POISED TO REPORT, IN DETAIL, WHAT HAPPENS WHEN THE TUMOR MICROENVIRONMENT IS EXPOSED TO DRUGS.
    PRESAGE IS THE ONLY COMPANY IN THE WORLD THAT ENABLES SAFE EVALUATION OF MULTIPLE DRUG CANDIDATES AND COMBINATIONS SIMULTANEOUSLY IN CANCER PATIENTS.
    WE UNRAVEL THE COMPLEXITY OF DRUG-TUMOR INTERACTIONS. WE ACCURATELY TRACK POSITIONS OF DRUG EXPOSURE AND EXAMINE RESPONSES THROUGH DETAILED SPATIAL MOLECULAR PROFILING.
    • PRESAGE BIOSCIENCES

      A Pioneer In Translational Oncology

      We bring innovation to cancer drug development. Our platform is uniquely capable of unraveling complexities of how patient tumors respond to drug exposure.
    • A bridge between preclinical insights and patient care

      The Forefront of Translational Medicine

      Using Presage's patented CIVO (Comparative In Vivo Oncology) platform, tumor microenvironment response to multiple investigational treatments, alone or in combination, can be observed where it matters most—in a patient's tumor.

    • Presage’s proprietary drug development platform

      The CIVO® Platform

      The CIVO (Comparative In Vivo Oncology) platform is an innovative translational oncology offering that encompasses a novel intratumoral delivery technology, a sophisticated operation, and highly detailed analysis. The platform is uniquely capable of providing comprehensive insights into the tumor microenvironment.
      [Downloader.la]-620b7b55ade30

      About Presage

      Presage’s patented CIVO® (Comparative In Vivo Oncology) technology delivers microdoses of multiple drugs to different regions of a tumor, while the tumor is still in the patient. Observing molecular and cellular responses to drugs and combinations in a naturally occurring tumor has the potential to provide a more detailed understanding of tumor biology, directly encompassing a patient’s own immune system, tumor microenvironment, and genetic background. It is Presage’s mission to improve the way that new drugs are developed and targeted, with the goal of ultimately providing more effective treatments to patients with cancer.

      Cancer Drug Development Needs More Predictive Platforms For Testing Candidate Agents

      One important bottleneck in oncology drug development is the inability of preclinical models to accurately model the tumor microenvironment in human patients.

      Preclinical CIVO Offerings Available

      CIVO highlights immune effects in syngeneic models

      Well-versed w/ over
      Tumor Models

      Approximately 1000 drugs and drug combinations evaluated

      Ability to run preclinical studies in-house

      Expert tumor modeling, histology, and image analysis staff

      Amenable to all injectable drug modalities

      Dedicated project management support

      Preclinical CIVO Offerings Available

      CIVO highlights immune effects in syngeneic models

      Team Members

      Fundamentally changing cancer
      drug development

      In a few simple steps, this patented process can simultaneously evaluate multiple drugs or
      drug combinations using 100+ assays for tumor microenvironment responses.

      CIVO IS A PIONEERING SOLUTION TO A HOST OF FUNDAMENTAL
      PROBLEMS INHERENT IN ONCOLOGY DRUG DISCOVERY

      Presage A Translational
      Oncology Company

      Nine issued US patents
      “A method of evaluating one or more candidate agents, wherein at least one of the one or more candidate agents is a drug, comprising: introducing the one or more candidate agents to one or more positions in a solid tissue, and; evaluating effectiveness of the candidate agents on the solid tissue, wherein the introducing step is in vivo, and wherein the solid tissue is a tumor.”

      Presage's Partners

      A pioneering solution, turnkey operation

      A pioneering solution, turnkey operation, revenue-generating partnerships2016 - 2021

      presage_logo-500px

      Connect With us

      Presage Biosciences
      530 Fairview Avenue North
      Suite 1000
      Seattle, WA 98109
      info@presagebio.com

      Copyright © 2024 Presage Biosciences | Developed by SteaTech | For research use only. Not for use in diagnostic procedures.